Kurzfassung

• To evaluate whether the outcome in children, young people and adults with HR-MB is improved
over standard therapy for those treated with: (i) conventional (once a day) radiotherapy (RT)
(standard therapy), (ii) hyperfractionated-accelerated radiotherapy (HART), or (iii) high-dose
therapy (HDT) with thiotepa followed by conventional RT.
• To evaluate whether the outcome in HR-MB is different for those treated with two different
maintenance chemotherapy therapies.